Intraperitoneal Delivery of Adaptive Natural Killer (NK) Cells (FATE-NK100) With Intraperitoneal Int

PHASE1CompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

October 19, 2017

Primary Completion Date

March 10, 2021

Study Completion Date

March 10, 2021

Conditions
Epithelial Ovarian CancerFallopian Tube CancerPrimary Peritoneal Cancer
Interventions
BIOLOGICAL

FATE-NK100

"FATE-NK100 Infusion (Day 0)~The FATE-NK100 product will be placed in approximately 100 cc of 5% human serum albumin.~* Dose Level 1: 1 x 10\^7 cells/kg IP~* Dose Level 2: \>1x10\^7 cells/kg to ≤3x10\^7 cells/kg~* Dose Level 3: Complete FATE-NK100 bag (≥3 x 10\^7 to ≤ 10 x 10\^7 cells/kg)"

DRUG

Interleukin-2

"Interleukin-2 (begin Day 0): 6 million units three times a week for a total of 6 doses. For patients weighing less than 45 kilograms, the IL-2 will be given at 3 million units/m2 three times a week for 6 doses.~The 1st dose will be given immediately (within 30 minutes) after the FATE-NK100 cell infusion on Day 0 as an inpatient. The remaining doses will be given in an outpatient setting."

Trial Locations (1)

55455

Masonic Cancer Center, University of Minnesota, Minneapolis

All Listed Sponsors
lead

Masonic Cancer Center, University of Minnesota

OTHER

NCT03213964 - Intraperitoneal Delivery of Adaptive Natural Killer (NK) Cells (FATE-NK100) With Intraperitoneal Int | Biotech Hunter | Biotech Hunter